Global & United States Cancer Therapeutics Market to 2031

In 2022, the American Cancer Society reported that over 1.9 million new cancer cases were diagnosed in the United States, resulting in approximately 610,000 deaths. By 2024, the number of new diagnoses is projected to reach around 2 million. Colorectal cancer ranks as the third most commonly diagnosed cancer among both men and women in the U.S., according to the American Society of Clinical Oncology. In 2023, about 150,000 adults were diagnosed with colorectal cancer, including 106,970 cases of colon cancer (54,420 in men and 52,550 in women) and 46,050 cases of rectal cancer (27,440 in men and 18,610 in women). This growing incidence of cancer highlights the urgent need for advanced treatment options such as immunotherapies and targeted therapies. The expanding patient population is a key factor driving growth in the cancer therapeutics market as healthcare providers seek more effective approaches to treatment.

Recent FDA approvals highlight the ongoing innovation in cancer treatment. In April 2024, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received FDA approval for the treatment of adults with unresectable or metastatic HER2-positive solid tumors who have not responded adequately to previous systemic therapies. In August 2023, the FDA approved a treatment regimen that combines the chemotherapy drugs trifluridine and tipiracil (Lonsurf) with the targeted therapy bevacizumab (Avastin) for patients with metastatic colorectal cancer who have already undergone multiple cycles of chemotherapy. Additionally, in November 2022, AstraZeneca's Imjudo (tremelimumab) was approved in combination with platinum-based chemotherapy for the treatment of Stage IV non-small cell lung cancer (NSCLC).

The growing adoption of novel therapies, especially immunotherapies and targeted treatments, is transforming cancer care. Many of these therapies are being fast-tracked by the FDA through initiatives like the Breakthrough Therapy Designation, accelerating their availability. Consequently, the combination of increasing cancer prevalence and proactive efforts by key industry players is expected to significantly boost the cancer therapeutics market in the forecast period.


1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Data Triangulation and Validation:
4. United States Cancer Therapeutics Market Landscape
4.1 Overview
4.2 Ecosystem Analysis
4.2.1 List of Vendors in the Value Chain
5. Cancer Therapeutics Market Key Market Dynamics
5.1 Cancer Therapeutics Market – Key Market Dynamics
5.2 Market Drivers
5.3 Market Restraints
5.4 Market Opportunities
5.5 Future Trends
5.6 Impact of Drivers and Restraints
6. United States Cancer Therapeutics Market – Analysis
6.1 United States Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
6.2 United States Cancer Therapeutics Market Revenue and Forecast Analysis
7. United States Cancer Therapeutics Market Analysis – by Therapy Types
7.1 United States Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
8. United States Cancer Therapeutics Market Analysis – by Indications
8.1 United States Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
9. United States Cancer Therapeutics Market Analysis – by Distribution Channel
9.1 United States Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
10. Competitive Landscape
10.1 Heat Map Analysis by Key Players
10.1 Company Positioning and Concentration
11. Industry Landscape
11.1 Overview
11.2 Market Initiative
11.2 Partnerships and Collaborations
11.2 Other Developments
12. Company Profiles
12.1 Bristol-Myers Squibb Co
12.1. 1 Key Facts
12.1. 2 Business Description
12.1. 3 Products and Services
12.1. 4 Financial Overview
12.1. 5 SWOT Analysis
12.1. 6 Key Developments
12.2 AbbVie Inc
12.2. 1 Key Facts
12.2. 2 Business Description
12.2. 3 Products and Services
12.2. 4 Financial Overview
12.2. 5 SWOT Analysis
12.2. 6 Key Developments
12.3 Johnson & Johnson
12.3. 1 Key Facts
12.3. 2 Business Description
12.3. 3 Products and Services
12.3. 4 Financial Overview
12.3. 5 SWOT Analysis
12.3. 6 Key Developments
12.4 F. Hoffmann-La Roche Ltd
12.4. 1 Key Facts
12.4. 2 Business Description
12.4. 3 Products and Services
12.4. 4 Financial Overview
12.4. 5 SWOT Analysis
12.4. 6 Key Developments
12.5 Pfizer Inc
12.5. 1 Key Facts
12.5. 2 Business Description
12.5. 3 Products and Services
12.5. 4 Financial Overview
12.5. 5 SWOT Analysis
12.5. 6 Key Developments
12.6 AstraZeneca Plc
12.6. 1 Key Facts
12.6. 2 Business Description
12.6. 3 Products and Services
12.6. 4 Financial Overview
12.6. 5 SWOT Analysis
12.6. 6 Key Developments
12.7 Merck KGaA
12.7. 1 Key Facts
12.7. 2 Business Description
12.7. 3 Products and Services
12.7. 4 Financial Overview
12.7. 5 SWOT Analysis
12.7. 6 Key Developments
12.8 Novartis AG
12.8. 1 Key Facts
12.8. 2 Business Description
12.8. 3 Products and Services
12.8. 4 Financial Overview
12.8. 5 SWOT Analysis
12.8. 6 Key Developments
12.9 Astellas Pharma Inc
12.9. 1 Key Facts
12.9. 2 Business Description
12.9. 3 Products and Services
12.9. 4 Financial Overview
12.9. 5 SWOT Analysis
12.9. 6 Key Developments
12.10 Eli Lilly and Co
12.10. 1 Key Facts
12.10. 2 Business Description
12.10. 3 Products and Services
12.10. 4 Financial Overview
12.10. 5 SWOT Analysis
12.10. 6 Key Developments
13. Appendix
13.1 About Business Market Insights
13.2 List of Abbreviations
TABLE OF TABLES
Table 1. United States Cancer Therapeutics Market Segmentation
Table 2. List of Vendors
Table 3. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
Table 4. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
Table 5. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
Table 6. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
Table 7. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
Table 8. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
Table 9. United States Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
Table 10. United States Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
Table 11. List of Abbreviations
TABLE OF FIGURES
Figure 1. Impact Analysis of Drivers and Restraints
Figure 2. United States Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
Figure 3. Heat Map Analysis by Key Players
Figure 4. Company Positioning and Concentration

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings